Navigation Links
Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
Date:5/1/2012

LAS VEGAS, May 1, 2012 /PRNewswire/ -- Noninvasive stereotactic ablative radiotherapy (SABR), a technical term for radiosurgery in the body, can be a viable option for treating operable cases of early-stage lung cancer, with outcomes that compare favorably to more invasive surgery, according to a study published in the May 2012 issue of the International Journal of Radiation Oncology, Biology, Physics.[1]

Speaking at a symposium sponsored by Varian Medical Systems (NYSE: VAR) in Las Vegas earlier this week, co-author Ben Slotman, M.D., Ph.D., of the VU University Medical Centre in Amsterdam reported that, for potentially operable patients with Stage I non-small cell lung cancer (NSCLC), SABR produced tumor control rates that are comparable to those achieved using surgery.   

Professor Slotman and his colleagues retrospectively reviewed records for lung cancer patients who were treated in his department between 2003 and 2010.  Among about 1,000 patients treated with SABR, the researchers identified 177 (101 males and 76 females) who could have been candidates for surgery but who instead received SABR.

"Among these patients, the one- and three-year survival rates were 95 percent and 85 percent respectively," said Dr. Slotman.  "The local tumor control rate after three years was 93 percent, and the median overall survival time was 61.5 months.  No patients died in the first 30 days after treatment.  Had these patients been treated surgically, we would have expected a 2.6 percent mortality rate, based on the Thoracoscore predictive model."[2]

Forty-two percent of patients in the study reported no early side effects with the SABR treatments. Those that did experience early side-effects experienced fatigue (25 percent), cough (14 percent), local chest wall pain (11 percent) and dyspnea (10 percent), with some patient
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
2. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
3. Retrospective Analysis Explores LYSTEDA®s Ability to Reduce Sleep Interruptions in Women With Cyclic Heavy Menstrual Bleeding
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... financial results for the second quarter ended June ... to see encouraging advancements in the US commercialization ... estimated total prescriptions and estimated total per week ... Arena,s President and Chief Executive Officer. "Other recent ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
(Date:7/31/2014)... Calif., July 31, 2014 Pharmacyclics, Inc. (the "Company") ... recent developments for the quarter ended June 30, 2014. ... June 30, 2014 Revenue Total revenue for the quarter ... million for the quarter ended June 30, 2013 primarily due ... million. Total revenue for the six months ...
Breaking Medicine Technology:Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26
(Date:8/1/2014)... (PRWEB) August 01, 2014 Growing ... coverage and healthcare reforms are boosting healthcare market ... medicines through discounts and increasing generic consumption is ... approximately 76.7 million in 2013, having grown at ... from 2008. The implementation of the Health Transformation ...
(Date:8/1/2014)... Hawley, PA (PRWEB) August 01, 2014 Hot ... in the destination spa category of the World’s Best ... kicks off a month-long celebration of National Relaxation Day (technically ... together a series of MAJOR experts to help guests celebrate ... how important it is for health and wellness to carve ...
(Date:8/1/2014)... The "Antimicrobial Coatings Market by ... Oxide, Titanium Dioxide, and Zinc Omadine), Application (Indoor ... & Beverages, Textiles, and others), & Geography (North ... and Forecasts to 2018" analyzes the Antimicrobial Coatings ... trends in the diverse geographical regions. , Browse ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. ... as a time-honored destination for a good cut and conversation. ... also be the spot to tackle an often overlooked health ... novel partnership, the U.S. Centers for Disease Control and Prevention, ... the help of barbershop staff to both discuss and diagnose ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
Breaking Medicine News(10 mins):Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4
... activates p53 tumor-suppressor function without causing DNA damage , , ... targets a protein interaction involved in many types of ... , In cell cultures, the small-molecule inhibitor MI-219 was ... protein p53 from being blocked in the presence of ...
... of Telehealth capabilities to the ... they help across Canada., TORONTO, March 7 /PRNewswire/ - ... announce they have partnered with We,Care Health Services Inc. "We ... of services for those with chronic diseases,and their caregivers. We ...
... HOLLYWOOD, Fla., March 7, Cancer,s two ... "costs," and each holds capacity,to create patient ... the National Comprehensive Cancer Network,s 13th Annual,Conference, ... treatments, best practices dictate that,they follow guidelines ...
... Grey House Publishing and Penn,Hill Publications, based in ... Hudson,s Washington News Media Contacts Directory. In addition ... Media Contacts,Directory, Grey House is also proud to ... Directory., In 1968, Howard Penn Hudson completed ...
... Galderma Pharma, S.A.,announces an agreement with ZARS ... outside the USA and Canada for promotion and,distribution ... follows,an agreement signed last year between Galderma and ... in the USA and Canada., "This agreement ...
... The rheumatoid arthritis (RA),treatment market, held back somewhat in ... and Bextra, is rebounding due to the,performance of biologic ... $12 billion in 2006 and -- driven by new ... year through 2011,according to a new report by Kalorama ...
Cached Medicine News:Health News:Researchers Design Promising Cancer Drug 2Health News:We Care Health Services Inc. partners with IgeaCare Systems Inc. to deliver Healthanywhere(TM) for Chronic Disease Management in Canada. 2Health News:We Care Health Services Inc. partners with IgeaCare Systems Inc. to deliver Healthanywhere(TM) for Chronic Disease Management in Canada. 3Health News:Is Cancer Community in Alignment About 'Cure' and 'Costs'? NCCN Conference Panel Asks 2Health News:Is Cancer Community in Alignment About 'Cure' and 'Costs'? NCCN Conference Panel Asks 3Health News:Grey House Publishing Acquires Hudson's Washington News Media Contacts Directory 2Health News:Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM) 2Health News:Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM) 3Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2
... collect sample, pipette into testing wells ... FDA 510K cleared multiple drug screen ... both drugs and adulterants. It can ... (5) drugs and can be accompanied ...
... Glucose Monitoring System is a patient insertable short-term ... the DexCom STS Receiver., The DexCom STS Sensor ... the DexCom STS Applicator by the user or ... held in place by an adhesive to the ...
... routine Holter,monitoring, the Burdick Vision ... a,practical, no-nonsense diagnostic tool ideal,for ... This highly accurate and,easy-to-use system ... configurations at a price even ...
... PC-based ECG diagnostics complements transition to ... the incorporation of computer-based technology into ... diagnostic instrumentation have developed. Burdick's Universal ... EMRs making it the ideal choice ...
Medicine Products: